Known case of mitral stenosis. Best agent to prevent thromboembolic event based on malaysian cpg
Reading File
Searching the Web
Malaysian CPG mitral stenosis anticoagulation thromboembolic prevention 2024
Finding Sources
Searching the Web
Malaysia MOH CPG valvular heart disease mitral stenosis warfarin anticoagulation guideline site:moh.gov.my OR site:acadmed.org.my
Reading Web Page
https://www.moh.gov.my/images/04-penerbitan/penerbitan-klini…
Finding Sources
I now have sufficient information from both the Malaysian CPG on AF (MOH/NHAM) and major textbooks to give a thorough, authoritative answer.
Antithrombotic Agent for Mitral Stenosis - Malaysian CPG Recommendation
The Answer: Oral Anticoagulation with a Vitamin K Antagonist (VKA) - Warfarin, targeting INR 2.0-3.0
Malaysian CPG Recommendation (MOH/NHAM - Management of Atrial Fibrillation)
The Malaysian MOH/NHAM CPG on Atrial Fibrillation gives a clear Class I, Level C recommendation:
"OAC therapy (INR 2.0-3.0) is indicated in patients with mitral stenosis and AF (paroxysmal, persistent, or permanent)."
Key points from the Malaysian CPG:
| Scenario | Recommendation | Class | Level |
|---|---|---|---|
| Mitral stenosis + AF (any type) | Warfarin, INR 2.0-3.0 | I | C |
| Mitral stenosis + sinus rhythm | Low threshold for anticoagulation; consider OAC | - | - |
| Mechanical valve (mitral position) | Warfarin, INR ≥ 2.5 | I | B |
Why Warfarin (VKA), NOT a NOAC/DOAC?
This is a critical distinction. Mitral stenosis (especially rheumatic in origin, which is the dominant etiology in Malaysia) is classified as valvular AF - a special category where:
- NOACs/DOACs are contraindicated - The EHRA classification places rheumatic mitral stenosis in the "EHRA Type 1 valvular AF" category, where evidence supports VKA only
- The INVICTUS trial (2022) confirmed warfarin is superior to rivaroxaban in rheumatic mitral stenosis + AF - rivaroxaban had higher rates of stroke/cardiovascular death without reduction in bleeding
- Stasis-driven thrombosis in the enlarged left atrium of mitral stenosis is mediated by factors different from non-valvular AF, and VKA works more reliably in this context
Major textbooks are unanimous: "Warfarin is required for patients with rheumatic mitral stenosis or mechanical heart valves" - Harrison's Principles of Internal Medicine 22E.
Indications for Anticoagulation in Mitral Stenosis (even WITHOUT AF)
The CPG and guidelines recommend considering OAC in sinus rhythm patients with any of the following:
- Prior thromboembolic event
- Left atrial thrombus on imaging
- Dense spontaneous echo contrast on TEE
- Markedly enlarged LA (diameter >55 mm)
Practical Summary
- Drug of choice: Warfarin (VKA)
- Target INR: 2.0-3.0 (aim for 2.5)
- NOACs are NOT recommended for rheumatic/moderate-to-severe mitral stenosis
- Aspirin alone is insufficient - not a valid alternative per guidelines
Note: There is no separate Malaysian CPG specifically dedicated to valvular heart disease as of 2026. The AF CPG (MOH/NHAM) and the NHAM guidelines largely follow ESC principles, which are consistent with the above recommendation.
This is a shared conversation. Sign in to Orris to start your own chat.